ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs


[End Subhead]
[Start Distributor]
Business Wire 14-Mar-2018 4:31 PM
[End Distributor]
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Companys expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 14-18, 2018 in Chicago.
ImmunoGen has in-depth expertise in all aspects of ADCs, which has resulted in the most comprehensive toolbox of ADC technologies in the industry, said Richard Gregory, Ph.D., ImmunoGens chief scientific officer. The data to be presented at AACR further build on our leadership position in the space and demonstrate continued innovation, including further advancements to payloads and targets for anti-tumor activity, as well as insights into factors that determine the clinical efficacy of ADCs.
Details of ImmunoGens poster presentations are as follows:
Title: A new class of DNA alkylating indolino-benzodiazepine agents (BIAs) linked with a DNA binding moiety for use with antibody-drug conjugates (ADCs) (abstract #747)Date:April 15, 2018Time: 1:00 5:00pm CT
A new class of DNA alkylating effector molecules for use in ADC development in which an IGN (indolino-benzodiazepine) monomer subunit is connected to a DNA binding moiety (e.g., Bi-Aryl, or Bis-Aryl) are termed BIAs. BIA ADCs displayed potent, antigen-specific in vitro activity across a panel of FR-expressing cell lines. In vivo, these ADCs demonstrated potent efficacy in xenograft models at doses well below the maximum tolerated dose.
Title: Development of an in vivo model system to assess the interplay between the various drivers of antibody drug conjugate (ADC) activity (abstract #753)Date:April 15, 2018Time: 1:00 5:00pm CT
To better understand the variables that impact ADC pharmacokinetics, tolerability, bio-distribution, and efficacy, a novel, cross-reactive model system was created. An anti-murine folate receptor alpha (FR) antibody was generated that binds to both mouse and human FR. The model system allows experiments to be designed in a cross-reactive system to examine how modifications to the antibody, linker or cytotoxic payload impact safety, and efficacy.
Title: Evaluation of endoglin/CD105 as a tumor vasculature target with antibody drug conjugates (abstract #2900)Date:April 16, 2018Time: 1:00 5:00pm CT
Endoglin/CD105 is a well-acknowledged endothelial cell proliferation marker, which is strongly expressed in tumor-associated vasculature. It was evaluated as an oncology target using ADCs of an anti-CD105 antibody with potent anti-microtubule maytansinoids DM1 and DM4, and the highly potent IGN DNA-alkylating payload, DGN549. Endoglin targeted huRH105-DM and huRH105-DGN549 conjugates produced modest anti-tumor activity and therapeutic indices in rat models.
Additional information and full abstracts can be found at www.aacr.org.
About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Companys lead product candidate, mirvetuximab soravtansine, is in the Phase 3 FORWARD I trial for FR-positive platinum-resistant ovarian cancer, and is in the Phase1b/2 FORWARD II trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roche's marketed product, Kadcyla, and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.
Kadcyla is a registered trademark of Genentech, a member of the Roche Group.
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the year endedDecember 31, 2017and other reports filed with theSecurities and Exchange Commission.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180314005853/en/
For Investors ImmunoGen, Inc. Sarah Kiely, 781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen, Inc.Courtney OKonek, 781-895-0600courtney.okonek@immunogen.comorFTI Consulting Inc.Robert Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
Source: ImmunoGen, Inc.

Wait, Before You Leave...